Papel actual de la biopsia prostática guiada por ultrasonido en el diagnóstico de cáncer de próstata
Palabras clave:
Cáncer de próstata, Biopsia prostática, Eficacia.Resumen
Introducción: El cáncer de próstata representa un serio problema de salud pública. La biopsia prostática constituye la herramienta para determinar su existencia. Objetivo: evaluar la utilidad actual de la biopsia prostática ecoguiada por vía transrectal en el diagnóstico de cáncer de próstata. Métodos: Se revisaron las biopsias de próstata doble sextante realizadas ecoguiadas por vía transrectal en el Hospital Universitario de Caracas en un período de 6 años. Resultados: El número total de biopsias revisadas fue de 2105. El porcentaje de biopsias positivas para malignidad fue de 29,12 %; y la cantidad de lesiones premalignas fue de 9,21 %. El Puntaje de Gleason más frecuentemente diagnosticado fue Gleason 7 (4+3) con un 30,34 %. La correlación biopsia preoperatoria y pieza de prostatectomía fue de 48 %. Conclusiones: La biopsia de próstata ecoguiada doble sextante nos permite de una forma sencilla y eficaz el diagnóstico inicial de cáncer de próstata significativo.
Descargas
Citas
Ministerio del Poder Popular para la Salud (MPPS). Programa de Oncología. Registro Central de Cáncer. Venezuela 2015.
Escudero JF, López P, Cao E, López AI, Maluff A, González PA. Eficacia clínica de la biopsia prostática. Experiencia en nuestro centro 1990-2002. Actas Urol Esp. 2008; 32(7): 713-16.
Wanabe H, Kato H, Kato T. Diagnostic application of the ultrasoundtomography for the prostate. Nippon Hinyokika Gakkai Zasshi. 1968; 59: 273-9.
Lee F. Torp-Pedersen ST, Siders DB. The role of transrectal ultrasound in the early detection of prostate cancer. CA Cancer J Clin. 1989; 39: 337-60.
Hodge KK, Mc Neal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of de prostate. J Urol. 1989; 142: 71-4.
Mottet N, Bellmunt J, Briers E, Van Den Bergh R, Bolla M, Van Casteren N, et al. Guidelines on Prostate Cancer. The Netherlands: European Association of Urology; 2017.
Trilla E, Morote J. Cáncer de próstata: nuevas técnicas diagnósticas. Estado actual de la biopsia de próstata. Arch Esp Urol. 2006; 59(10): 945-52.
Di Franco C, Jallous H, Porru D, Giliberto G, Cebrelli T, Tinelli C, et al. A retrospective comparison between transrectal and transperineal prostate biopsy in the detection of prostate cáncer. Arch Ital Urol Androl. 2017; 89(1): 55-9.
Huang H, Wang W, Lin T, Zhang O, Zhao X, Lian H, et al. Comparison of the complications of traditional 12 cores transrectal prostate biopsy with image fusion guided transperineal prostate biopsy. BMC Urology. 2016; 16: 68.
Ozcan S, Akif Diri M, Bagcioglu M, Karakan T, Aydın A. Complications and prostate cancer diagnosis rate of TRUS prostate biopsies using 16 and 18G needles by Clavien scoring. Urol. 2017; 84(4): 236-9.
Van Hove A, Savoie PH, Maurin C, Brunelle S, Gravis G, Salem N, et al. Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies. World J Urol. 2014; 32(4): 847-58.
Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur Urol. 2015; 68(3): 438-50.
Mertan FV, Greer MD, Shih JH, George AK, Kongnyuy M, Muthigi A, et al. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection. J Urol. 2016; 196(3): 690-6.
Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389(10071): 815-22.
Branger N, Maubon T, Traumann M, Thomassin-Piana J, Brandone N, Taix S, et al. Is negative multiparametric magnetic resonance imaging really able to exclude significant prostate cancer? The real-life experience. BJU Int. 2017; 119(3): 449-55.
Siddiqui MM, Rais-Bahrami S, Turkbey B, Arvin G, Rothwax J, Shakir N, et al. Comparison of MR/ ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. J Amer Med Asoc. 2015; 313: 390-7.
Pokorny MR, de Rooij M, Duncan E, Schröder FH, Parkinson R, Barentsz JO, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2014; 66: 22-9.
Yang T, Zhang L, Chen Y, Cai Y, Jiang H, Ding Q. The predictive efficacy of hypoechoic lesion in ultrasound for prostate cancer in Chinese people: five-year experience in a moderated 10-core transperineal prostate biopsy procedure. Oncotarget. 2017; 8(45): 79433-40.
Pahwa S, Schiltz NK, Ponsky LE, Lu Z, Griswold MA, Gulani V. Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men. Radiol. 2017; 17: 162181.
Venderink W, Govers TM, de Rooij M, Fütterer JJ, Sedelaar JPM.Cost-Effectiveness Comparison of Imaging-Guided Prostate Biopsy Techniques: Systematic Transrectal Ultrasound, Direct In-Bore MRI, and Image Fusion. AJR Am J Roentgenol. 2017; 208(5): 1058-63.
Bansal S, Gupta N, Yadav R, Khera R, Ahlawat K, et al. Multiparametric magnetic resonance imaging-transrectal ultrasound fusion prostate biopsy: A prospective, single centre study. Indian J Urol. 2017; 33(2): 134–9.
Klemann N, Røder MA, Helgstrand JT, Brasso K, Toft BG, Vainer B, et al. Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study. Lancet Oncol. 2017; 18(2): 221-9.
Tadtayev S, Hussein A, Carpenter L, Vasdev N, Boustead G. The association of level of practical experience in transrectal ultrasonography guided prostatebiopsy with its diagnostic outcome. Ann R Coll Surg Engl. 2017; 99(3): 218-23.
Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. A cutoffs to enhance detection of curable prostate cancer. Urol. 2000; 55(6): 791-5.
Djavan B, Milani S, Remzi M. Prostate biopsy: who, how and when. An update. Can J Urol. 2005; 12(1): 44-8.
Schröder FH, Roobol-Bouts M, Vis AN, Van Der Kwast T, Kranse R. Prostat specific antigen based early detection of prostate cancer validation of screening without rectal examination. Urol. 2001; 57(1): 83-90.
Raghunath S, Pawar P, Somaji A, Vijay A, Narwade S, Tanaji S, et al. TRUS Biopsy Yield in Indian Population: A Retrospective Analysis. J Clin Diagn Res. 2017; 11(2): PC01-PC05.
Levine MA, Ittman M, Melamed J. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol. 1998; 159(2): 471-476.
Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM, et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001; 165(5): 1554-9.
Chang JJ, Shinohara K, Bhargava V, Presti JC Jr. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol. 1998; 160(6 Pt 1): 2111-4.
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016; 40(2): 244-52.
Reyes Y. Castro M, Guerrero G. Eficacia de la biopsia transrectal guiada por ultrasonido con técnica extensa. Anal Radiol Méx. 2009; 2: 177-81.
Etxezarraga C, López J. Importancia clínica del diagnóstico de neoplasia intraepitelial prostática de alto grado y del de proliferación microglandular atípica en biopsias transrectales. Rev Esp Patol. 2008; 41(1): 35-40.
Tapia O, Bellolio E, Roa J, Guzmán P, Villaseca M, Araya J. Puntaje de gleason en cáncer de próstata: correlación de la biopsia por punción y prostatectomía radical. Rev Med Chile. 2011; 139: 171-6.
Arellano L, Castillo O, Metrebián E. Concordancia diagnóstica del puntaje de Gleason en biopsia por punción y prostatectomía radical y sus consecuencias clínicas. Rev Méd Chile. 2004; 132: 971-8.
Walker R, Lindner U, Louis A, Kalnin R, Ennis M, Nesbitt M. Concordance between transrectal ultrasound guided biopsy results and radical prostatectomy final pathology: Are we getting better at predicting final pathology? Can Urol Assoc J. 2014; 8(1-2): 47-52.
Kvåle R, Møller B, Wahlqvist R. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int. 2009; 103: 1647-54.
Mian BM, Lehr DJ, Moore CK. Role of prostate biopsy schemes in accurate prediction of Gleason scores. Urol. 2006; 67: 379-83.
Capitanio U, Karakiewicz PI, Valiquette L. Biopsy core number represents one of foremost predictors of clinically significant Gleason sum upgrading in patients with low-risk prostate cancer. Urol. 2009; 73: 1087-91.
Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol. 2001; 166: 104-9.
Rajinikanth A, Manoharan M, Soloway CT, Civantos FJ, Soloway MS. Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. Urol. 2008; 72: 177-82.
Altay B, Kefi A, Nazli O, Killi R, Semerci B, Akar I. Comparison of Gleason scores from sextant prostate biopsies and radical prostatectomy specimens. Urol Int. 2001; 67: 14-8.
Montesino M, Jiménez J, Repáraz B, Ruiz M, Villanueva I, Hualde A., et al. Correlation between Gleason score on prostate biopsies diagnostic of adenocarcinoma and radical prostatectomy specimens. Arch Esp Urol. 2004; 57: 519-23.
Rodríguez O, Fernández JM, Guate JL, Martín JL, Pérez FJ, García J, et al. Assessment of the Gleason score in biopsies and specimens of radical prostatectomy. Arch Esp Urol. 2003; 56: 781-4.
Algaba Arrea F, Chivite de León A, Santaularia Segura JM, Oliver Samper A. Evidence of the radical prostatectomy Gleason score in the biopsy Gleason score. Actas Urol Esp. 2004; 28: 21-6.
Arrabal-Polo M, Jiménez A, Mijan J, Arrabal-Martín M, Díaz F, Carmona F, et al. Relación entre score Gleason biópsico y score Gleason tras prostatectomía radical en pacientes sometidos a biopsia sextante vs 12 cilindros. Arch Esp Urol. 2010; 63(9): 791-6.
Evans SM, Patabendi Bandarage V, Kronborg C, Earnest A, Millar J, Clouston D. Gleason group concordance between biopsy and radical prostatectomy specimens: A cohort study from Prostate Cancer Outcome Registry - Victoria. Prostate Int. 2016; 4(4): 145-51.
Arellano L, Castillo O, Metrebián E. Concordancia diagnóstica del puntaje de Gleason en biopsia por punción y prostatectomía radical y sus consecuencias clínicas. Rev Méd Chile. 2004; 132: 971-8.
Treurniet KM, Trudel D, Sykes J, Evans AJ, Finelli A, Van der Kwast TH. Downgrading of biopsy based Gleason score in prostatectomy specimens. J Clin Pathol. 2014; 67(4): 313-8.
Porpiglia F, De Luca S, Passera R, Manfredi M, Mele F, Bollito E, et al. Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score. Anticancer Res. 2016; 36(9): 4833-9.
Bostwick DG, Bostwick KC. "Vanishing" prostate cancer in radical prostatectomy specimens: incidence and long term follow up in 38 cases. BJU Int. 2004; 94(1): 57-8.
Cómo citar
Número
Sección
Licencia
Usted es libre de:
- Compartir — copiar y redistribuir el material en cualquier medio o formato
- Adaptar — remezclar, transformar y construir a partir del material
- para cualquier propósito, incluso comercialmente.
Bajo los siguientes términos:
-
Atribución — Usted debe dar crédito de manera adecuada, brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
- No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
